Biomea Fusion
Biomea Fusion (NASDAQ: BMEA) is a clinical-stage diabetes and obesity medicines company developing oral covalent small-molecule drugs, led by icovamenib (BMF-219), a covalent menin inhibitor. The COVALENT program spans Phase 2 trials in type 1 and type 2 diabetes; on August 24, 2026 the company announced completion of enrollment in COVALENT-211 (icovamenib in insulin-deficient type 2 diabetes), and on August 13, 2026 it announced first-patient-dosed in the OPAL study evaluating icovamenib in combination with semaglutide in obesity. The pipeline also includes BMF-650, a Phase 1 GLP-131 candidate for obesity. Incorporated in 2017 and headquartered in San Carlos, California, Biomea Fusion listed on Nasdaq in April 2021.
Company Info
Upcoming Milestones & Key Dates
COVALENT-211 Phase 2 enrollment completed (icovamenib in insulin-deficient type 2 diabetes)
OPAL study first patient dosed (icovamenib + semaglutide in obesity)
Clinical Development Pipeline
Icovamenib (BMF-219)
Target: Covalent menin inhibitor (oral)Icovamenib + semaglutide
Target: Covalent menin inhibitor + GLP-1 combinationBMF-650
Target: GLP-131 (glucagon-like peptide-1)Recent News
No recent news updates available for this company.
Leadership Team
Michael J. M. Hitchcock, Ph.D.
Interim Chief Executive Officer and Director
Ramses M. Erdtmann
Co-Founder, President, Chief Operating Officer and Director
Stephan Morris, M.D.
Chief Development Officer